🔍

Sanofi Consumer Healthcare India Limited (SANOFICONR)

₹3,548.70 -0.69% last close, 16 Oct

📊 NSE: SANOFICONR 🏢 Pharmaceuticals - Multinational 📢 Latest filing: 12 Oct 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Sanofi Consumer's revenue was ₹236 Cr (+6.7% year on year, +2.9% on the previous quarter), and net profit ₹68.8 Cr (+12.8% year on year); the operating margin was 37.9%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹236	+6.7%	+2.9%
Operating profit	₹89.3	+27.6%	+0.3%
Net profit	₹68.8	+12.8%	+1.2%
EPS (₹)	29.87	+13.3%	+1.5%
Operating margin	37.9%	—	—

Full quarterly financials → Results calendar →

SANOFICONR delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 58.2% of the SANOFICONR shares traded on NSE were taken to delivery, against the stock's own 20-session average of 54.17%. That is close to its usual level. Turnover was only ₹79 lakh, so a handful of trades can move this figure. Volume was 0.3 times its average, well below normal.

58.2%Delivery, 16 Oct

54.17%Own 20-session average

0.3×Volume vs its average

₹3,548.70NSE close · -0.69%

Delivery in the last 5 sessions: 50.6% · 51.7% · 62.1% · 48.2% · 58.2%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Sanofi Consumer Healthcare Submits Demat Compliance Certificate for Q2 FY27

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 12 Oct 2026, 03:30 PM

Sanofi Consumer Healthcare India Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026. The certificate was issued by Registrar and Share Transfer Agent MUFG Intime India Private Limited on 3rd October 2026. It confirms that share certificates received for dematerialisation were duly processed, verified, and cancelled within prescribed timelines. This is a regular administrative quarterly filing with no impact on business operations or financials.

Compliance certificate submitted for the quarter ended 30th September 2026
Issued by RTA MUFG Intime India Private Limited dated 3rd October 2026
Filing submitted to BSE and NSE on 12th October 2026

💡 No action is required as this is a recurring regulatory compliance filing; investors should track upcoming Q2 financial results.

Sanofi Consumer Q2 Net Profit Up 13% to ₹68.8 Cr; Domestic Sales Grow 12%

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 28 Jul 2026, 08:09 PM

Sanofi Consumer Healthcare India (SCHIL) reported a 7% YoY revenue growth to ₹235.7 cr for Q2 2026, driven by a strong 12% increase in domestic sales following product relaunches. Net profit for the quarter rose 13.3% to ₹68.8 cr, while Profit Before Tax (PBT) grew 16% YoY to ₹91.9 cr. The first half of 2026 (H1) shows stronger momentum with revenue up 18% and PBT up 25% YoY. The company maintains a robust liquidity position with cash and bank balances of ₹490.2 cr as of June 30, 2026.

Revenue from operations grew 7% YoY to ₹2,357 million in Q2 2026.
Domestic sales increased by 12% YoY, benefiting from the successful relaunch of previously recalled products.
Profit Before Tax (PBT) rose 16% YoY to ₹919 million, reflecting improved operational efficiency.
H1 2026 revenue reached ₹4,649 million, a significant 18% growth over the previous year's half-yearly performance.
Cash and cash equivalents increased to ₹4,902 million from ₹3,748 million in December 2025.

💡 Investors should monitor the sustainability of the 12% domestic growth as the 'relaunch' impact normalizes and track the recovery of export sales, which declined 9% this quarter due to a high base.

13% Net Profit Growth in Q2 2026; Domestic Sales Up 12% YoY on Product Relaunches

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 28 Jul 2026, 07:45 PM

Sanofi Consumer Healthcare India (SCHIL) reported a 7% YoY increase in revenue to ₹235.7 Cr for the quarter ended June 30, 2026. Net profit grew by 13.3% to ₹68.8 Cr, while Profit Before Tax (PBT) rose 16% to ₹91.9 Cr. Growth was primarily driven by the domestic market, which saw a 12% increase following the successful relaunch of previously recalled products. Despite a 9% dip in quarterly exports due to a high base, the half-year (H1) performance remains robust with total revenue up 18% and PBT up 25%.

Revenue from operations grew 7% YoY to ₹235.7 Cr in Q2 2026.
Domestic sales increased by 12% YoY, aided by the re-establishment of key brands in the market.
Profit Before Tax (PBT) reached ₹91.9 Cr, a 16% increase over the same quarter last year.
Half-year (H1) revenue reached ₹464.9 Cr, representing an 18% growth compared to H1 2025.
Cash and cash equivalents significantly increased to ₹490.2 Cr as of June 30, 2026, from ₹374.8 Cr in December 2025.

💡 Investors should monitor the sustainability of the 12% domestic growth rate and watch for any regulatory updates regarding OTC drug classifications in India, which could impact distribution.

June 30, 2026: Sanofi Consumer Healthcare Files Quarterly Share Dematerialization Certificate

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Jul 2026, 03:42 PM

Sanofi Consumer Healthcare India Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Intime India Private Limited, confirms that all securities received for dematerialization during the quarter ended June 30, 2026, were processed within prescribed timelines. This filing confirms that the name of the depositories has been substituted in the register of members as the registered owner for the processed shares. This is a standard administrative procedure for listed companies and has no impact on business fundamentals.

Compliance certificate issued for the quarter ended June 30, 2026
Registrar MUFG Intime India Private Limited issued the confirmation on July 1, 2026
Securities received for dematerialization were confirmed/rejected within prescribed timelines
Confirmation that dematerialized securities are listed on the BSE and NSE
Official filing submitted to exchanges on July 9, 2026

💡 This is a routine regulatory filing. Investors should monitor the company's upcoming quarterly financial results for any material changes in business performance.

Sanofi Consumer Healthcare Appoints PwC as Statutory Auditor for 5-Year Term

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 29 Jun 2026, 09:34 PM

Sanofi Consumer Healthcare India Limited has appointed M/s. Price Waterhouse & Co Chartered Accountants LLP (PwC) as its statutory auditor. This appointment, approved at the 3rd AGM on June 26, 2026, fills the casual vacancy created by the resignation of Kalyaniwalla & Mistry LLP. PwC will serve a five-year term concluding at the 8th AGM in 2031. This transition to a 'Big 4' audit firm aligns with the company's status as a listed multinational subsidiary.

Appointment of Price Waterhouse & Co (PwC) for a 5-year consecutive term until 2031
Shareholder approval secured at the 3rd Annual General Meeting held on June 26, 2026
PwC replaces outgoing auditor Kalyaniwalla & Mistry LLP following their resignation
The firm PwC has over 120 Assurance Partners as of April 1, 2026
Q3 2025 Net Profit was reported at INR 62.9 Cr, a 40% increase YoY

💡 Investors should monitor future financial disclosures for any changes in accounting notes or reporting styles under the new auditors, though no material impact on operations is expected.

Rs 75 Dividend Approved; Sanofi Consumer Healthcare Shareholders Pass All AGM Resolutions

🟡 NEUTRAL ⭐ 5/10

ROUTINE 📅 29 Jun 2026, 07:17 PM

Sanofi Consumer Healthcare India Limited (SCHIL) has concluded its 3rd Annual General Meeting, with shareholders approving all proposed resolutions. A significant final dividend of Rs 75 per equity share for the financial year ended December 31, 2025, was ratified. While all resolutions passed, the appointment of Price Waterhouse & Co as Statutory Auditors saw notable institutional dissent at 42.72%, though it passed with an overall 91.27% majority. The company remains focused on its 'India for India' strategy following the global Opella group restructuring.

Approved a final dividend of Rs 75 per equity share for the financial year ended December 31, 2025
Total of 49,698 shareholders were on record for the meeting held on June 26, 2026
Resolution to appoint Price Waterhouse & Co as Statutory Auditors passed with a 91.27% overall majority
Institutional investors cast 1,799,851 votes (42.72%) against the appointment of Statutory Auditors in Resolution 4
Promoter group, holding 16,414,217 shares, voted 100% in favor of all six resolutions

💡 Investors should monitor the dividend credit timeline and watch for the next quarterly results to verify if the 13% expected growth rate is being met through the 'India for India' strategy.

Sanofi Consumer Healthcare India Approves Rs 75 Dividend at 3rd AGM

🟢 POSITIVE ⭐ 7/10

ROUTINE 📅 26 Jun 2026, 07:20 PM

Sanofi Consumer Healthcare India Limited (SANOFICONR) successfully conducted its 3rd Annual General Meeting on June 26, 2026. A key outcome was the approval of a substantial final dividend of Rs. 75 per equity share for the financial year ended December 31, 2025. The company also confirmed the appointment of Price Waterhouse & Co as statutory auditors and re-appointed Mr. Stanislas Camart as a Director. Management addressed shareholder queries regarding the company's 2025 financial performance and future strategic initiatives.

Approval of a final dividend of Rs. 75 per equity share of face value Rs. 10 for FY2025
Adoption of audited standalone financial statements for the year ended December 31, 2025
Appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP as Statutory Auditors
Re-appointment of Mr. Stanislas Camart as Director following his retirement by rotation
Management provided a strategic overview of business performance and key developments to shareholders

💡 Investors should track the record date for the Rs. 75 dividend to ensure eligibility for this high-yield payout. The company's ability to maintain such dividends should be monitored alongside its standalone growth performance.

Sanofi Consumer Healthcare to Close Trading Window from July 1, 2026, for Q1/H1 FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Jun 2026, 12:25 PM

Sanofi Consumer Healthcare India Limited has announced the closure of its trading window starting July 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is ahead of the declaration of the company's unaudited standalone financial results for the quarter and half-year ending June 30, 2026. The trading window will remain closed for all designated persons until 48 hours after the financial results are officially released to the stock exchanges. This is a standard regulatory procedure and does not indicate any fundamental change in the company's operations.

Trading window closure to commence on July 1, 2026.
Closure pertains to the announcement of Unaudited Standalone Financial Results for the period ending June 30, 2026.
The window will reopen 48 hours after the results are disclosed to BSE and NSE.
Compliance is maintained under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 No action is required as this is a routine regulatory filing. Investors should look out for the upcoming board meeting date announcement for the actual financial performance results.

Sanofi Consumer Healthcare India to Hold 3rd AGM; Proposes ₹75 Final Dividend

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 04 Jun 2026, 11:00 PM

Sanofi Consumer Healthcare India Limited (SANOFICONR) has scheduled its 3rd Annual General Meeting for June 26, 2026. The Board has recommended a substantial final dividend of ₹75 per equity share for the financial year ended December 31, 2025. The record date for dividend eligibility is June 19, 2026, with the payment scheduled for July 9, 2026. Other key agenda items include the appointment of Price Waterhouse & Co as Statutory Auditors for a five-year term.

Recommended a final dividend of ₹75 per equity share of ₹10 each for FY 2025.
3rd Annual General Meeting (AGM) scheduled for June 26, 2026, via Video Conferencing.
Record date for dividend entitlement is June 19, 2026; payout date is July 9, 2026.
Proposed appointment of Price Waterhouse & Co Chartered Accountants LLP as Statutory Auditors for 5 years.
Ratification of ₹3,15,000 remuneration for Cost Auditors M/s. Kishore Bhatia & Associates for FY 2026.

💡 Investors should ensure their bank details and tax residency documents are updated with the RTA by June 19, 2026, to receive the ₹75 dividend. The high dividend payout reflects strong cash flow and shareholder focus.

Sanofi Consumer Healthcare Sets June 19, 2026, as Record Date for Final Dividend

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 27 May 2026, 06:43 PM

Sanofi Consumer Healthcare India Limited has announced the timeline for its final dividend for the financial year 2025. The company has fixed June 19, 2026, as the record date to determine shareholder eligibility for the payout. The 3rd Annual General Meeting (AGM) is scheduled for June 26, 2026, via video conferencing. The register of members will remain closed from June 20 to June 26, 2026, for the purpose of this dividend distribution.

Record date for FY 2025 final dividend is fixed as June 19, 2026
Book closure period scheduled from June 20, 2026, to June 26, 2026
3rd Annual General Meeting (AGM) to be held on June 26, 2026, at 3:00 p.m. IST
Dividend will be paid to beneficial owners as per NSDL and CDSL records as of June 19, 2026

💡 Investors seeking the final dividend should ensure they hold shares in their demat accounts before the record date of June 19, 2026. Monitor the upcoming Annual Report for the specific dividend amount per share.

Sanofi Consumer Healthcare Sets June 19, 2026, as Record Date for Final Dividend

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 27 May 2026, 06:34 PM

Sanofi Consumer Healthcare India Limited (SANOFICONR) has announced June 19, 2026, as the record date for determining shareholder eligibility for its final dividend for the financial year 2025. The company's 3rd Annual General Meeting (AGM) is scheduled to take place on June 26, 2026, via video conferencing. Share transfer books will remain closed from June 20 to June 26, 2026, to facilitate the dividend payment process. This corporate action follows the company's recent listing and operational updates.

Record date for the final dividend is fixed as Friday, June 19, 2026.
The 3rd Annual General Meeting (AGM) will be held on Friday, June 26, 2026, at 3:00 p.m. IST.
Register of Members and Share Transfer Books will be closed from June 20, 2026, to June 26, 2026.
The dividend will be paid to shareholders whose names appear as beneficial owners at the close of business on the record date.

💡 Investors interested in the dividend should ensure they hold the company's shares before the ex-dividend date, typically one day prior to the June 19 record date. Shareholders should also review the upcoming Annual Report for the specific dividend amount and financial performance details.

Sanofi Consumer Healthcare India Sets June 19 as Record Date for Final Dividend

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 27 May 2026, 06:30 PM

Sanofi Consumer Healthcare India Limited (SANOFICONR) has announced its 3rd Annual General Meeting (AGM) scheduled for June 26, 2026. The company has fixed June 19, 2026, as the Record Date to determine shareholder eligibility for the final dividend for the financial year 2025. The Register of Members and Share Transfer Books will remain closed from June 20 to June 26, 2026. This routine corporate action confirms the timeline for shareholder payouts following the company's recent demerger and listing processes.

3rd Annual General Meeting (AGM) to be held on June 26, 2026, at 3:00 p.m. IST.
Record date for final dividend eligibility is fixed as Friday, June 19, 2026.
Book closure period for dividend and AGM is from June 20, 2026, to June 26, 2026.
The meeting will be conducted via Video Conferencing/Other Audio-Visual Means.
Final dividend payment is subject to shareholder approval at the upcoming AGM.

💡 Investors interested in the final dividend should ensure they hold the stock before the record date of June 19, 2026. Existing shareholders should review the upcoming Annual Report for the specific dividend amount and growth guidance.

Sanofi Consumer Healthcare Appoints PwC as Statutory Auditor for 5-Year Term

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 25 May 2026, 06:03 PM

Sanofi Consumer Healthcare India Limited has appointed Price Waterhouse & Co Chartered Accountants LLP (PwC) as its new Statutory Auditor. This appointment fills the casual vacancy created by the resignation of M/s. Kalyaniwalla & Mistry LLP on April 30, 2026. The Board has also recommended PwC for a full five-year term from 2026 to 2031, subject to shareholder approval at the upcoming Annual General Meeting. The transition to a Big Four affiliate firm is typically seen as a positive step for enhancing corporate governance and financial reporting credibility.

Appointment of PwC to fill casual vacancy effective May 25, 2026, until the next AGM.
Recommended 5-year term for PwC starting from the 2026 AGM through to the 2031 AGM.
The change follows the resignation of previous auditors M/s. Kalyaniwalla & Mistry LLP on April 30, 2026.
PwC India network has over 120 Assurance Partners and 17 branch offices as of April 2026.

💡 Investors should view the appointment of a globally recognized audit firm as a positive governance move. No immediate action is required other than noting the change for future financial reporting cycles.

Sanofi Consumer Healthcare Statutory Auditor Resigns Due to Audit Fee Dispute

🔵 WATCH ⭐ 6/10

REGULATORY 📅 30 Apr 2026, 05:53 PM

M/s. Kalyaniwalla & Mistry LLP has resigned as the statutory auditor of Sanofi Consumer Healthcare India Limited, effective April 30, 2026. The firm cited the commercial unviability of continuing the audit after the company declined a requested fee increase for FY 2026. The auditors were originally appointed for a five-year term ending in 2028. Notably, the outgoing auditors confirmed there are no other material concerns or issues with obtaining audit evidence.

Statutory Auditor M/s. Kalyaniwalla & Mistry LLP resigned effective April 30, 2026.
The resignation follows the company's refusal to accommodate a fee increase requested on April 25, 2026.
The auditor was in the second year of a five-year term originally scheduled to run from 2024 to 2028.
Auditor confirmed no concerns regarding financial statements or inability to obtain audit evidence.

💡 Investors should monitor the appointment of a successor auditor to ensure a smooth transition. While auditor resignations can be a red flag, the explicit mention of a fee dispute suggests this is a commercial disagreement rather than a sign of financial irregularity.

Sanofi Consumer Healthcare Q1 26: Revenue Up 33% to ₹2,292 MN, PAT Rises 36%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 30 Apr 2026, 12:36 PM

Sanofi Consumer Healthcare India (SCHIL) reported a strong Q1 2026 with total revenue reaching ₹2,292 million, a 33% year-on-year increase. Net profit for the quarter grew by 36% to ₹678 million, reflecting disciplined execution and market share gains. Domestic sales were up 15.5%, significantly aided by the relaunch of recalled products, while export sales surged 144% due to a low base effect. This performance marks a positive trajectory for the company following its demerger from Sanofi India in June 2024.

Total Revenue grew 33% YoY to ₹2,292 million in Q1 2026
Net Profit (PAT) increased by 36% YoY to ₹678 million
Domestic sales grew by 15.5%, supported by product relaunches and market share gains
Export sales saw a significant 144% growth, primarily due to a low base in the previous year
Key brands like Allegra, DePURA, Avil, and Combiflam continue to drive the consumer healthcare portfolio

💡 The strong double-digit growth in both top-line and bottom-line suggests the demerged entity is scaling well; investors should monitor the sustainability of domestic volume growth. The successful relaunch of recalled products is a key positive catalyst for future quarters.

View All SANOFICONR Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single business segment, 'Pharmaceutical Business'. For Q3 2025, revenue was INR 233.9 Cr, representing a 46% YoY growth. For the nine months ended September 2025, revenue reached INR 627.4 Cr, up 13% YoY.

Geographic Revenue Split

In Q3 2025, Domestic sales grew by 20% YoY, while Export sales grew by 1031% YoY on a low base. For the nine-month period, Domestic sales grew by 1% and Export sales grew by 96% YoY.

Profitability Margins

For CY 2024, the Operating Profit Margin was 35% (down from 39% in 2023) and the Net Profit Margin was 25% (down from 30% in 2023). Q3 2025 Net Profit was INR 62.9 Cr, a 40% increase YoY.

EBITDA Margin

In CY 2024, the company achieved an EBITDA of INR 255.2 Cr with an EBITDA margin of 35%. Core profitability remains strong despite a slight margin compression compared to the restated 2023 figures.

Credit Rating & Borrowing

Not disclosed in available documents; however, the company reported a Debt-Equity ratio of 'NA', indicating a debt-free balance sheet.

⚙️ Operational Drivers

Operational analysis data not yet available for this company.

📈 Strategic Growth

Expected Growth Rate

13%

Growth Strategy

Growth is driven by the 'India for India' strategy, leveraging global Opella expertise to implement local Consumer Healthcare (CHC) strategies. Key drivers include the successful re-establishment of voluntarily recalled products and active engagement with regulators to shape OTC regulations in India. The transition to a standalone entity under CD&R ownership (50% stake) aims to enhance local agility and decision-making.

Products & Services

Consumer healthcare and pharmaceutical products (OTC medicines).

New Products/Services

The company focused on re-establishing voluntarily recalled products within the year, which have successfully regained market presence.

Market Expansion

Focus on the Indian domestic market, which saw 20% growth in Q3 2025, and expanding export reach from a low base.

Strategic Alliances

The company demerged from Sanofi India Limited in June 2024. Globally, Sanofi sold a 50% controlling stake in the parent Opella group to Clayton, Dubilier & Rice (CD&R) in April 2025.

🌍 External Factors

Industry Trends

The Indian consumer healthcare sector is shifting toward standalone specialized entities. Regulatory evolution in OTC frameworks is a key trend, with the company actively participating in shaping these norms to increase self-care accessibility and market reach.

Competitive Moat

The moat is derived from global science-based self-care expertise via the Opella group and a resilient brand portfolio that successfully recovered from product recalls. The 'India for India' strategy provides local agility while maintaining global quality standards.

Consumer Behavior

Increasing consumer demand for simpler, more accessible, and more effective self-care solutions.

⚖️ Regulatory & Governance

Industry Regulations

The company is actively engaged with regulatory authorities to help shape Over-the-Counter (OTC) regulations in India, which is critical for its standalone consumer healthcare strategy.

Legal Contingencies

No material fines, penalties, or settlement amounts were paid to regulators or law enforcement agencies in CY 2024.

⚠️ Risk Analysis

Key Uncertainties

Key risks include regulatory shifts in OTC drug classifications and potential product quality issues or recalls, which can disrupt market presence for up to a year.